NEW DELHI: The number of clinical trials in the country is increasing according to the data of the last ten years since 2014. Experts suggest that the increase in numbers during this period is due to the ease with which clinical tests are conducted and the speed and acceptance have increased.

Figures show that Phase Two and Phase Three clinical trials have grown from 15 percent to 18 percent. Badri Srinivasan, head of Novartis Global Clinical Operations, said the 10 amendments to the Drugs and Cosmetics Act 1940 were the main reason for this change.

Badri Srinivasan said that the central government is also adopting a policy of conducting more clinical trials depending on the changes in the emotional level. He pointed out that more modernization is going on in the health sector in the country. This will make clinical trials more transparent, standardized and easy.

He also said that modernization would also be beneficial in terms of what ethics committees can do and how compensation should be. Novartis is one of the largest pharmaceutical companies in the world. Novartis is the world’s fourth largest pharmaceutical company by revenue in 2022.

Hospital chains and hospital networks in the country are becoming part of the modernization of the health sector. 70% of patients in India rely on private hospitals. In addition to major cities, hospital networks have also expanded to second and third tier cities.

Through this, more patient information will be part of this network. All this has made India a favourite destination for clinical trials, says Badri Srinivasan.